Navigation Links
Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
Date:3/12/2010

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave.  The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
(Date:12/17/2014)... , December 17, 2014 Revenue ... of expenditure on research and development In the ... its revenue by two percent to EUR 4.287 billion (last ... grew by 14 percent to EUR 360 million. "Overall, 2013/14 ... Dr. Michael Kaschke , President and CEO of Carl ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:12/21/2014)... 22, 2014 Weddingshe.com, an outstanding online ... has recently released its new selection of Cocktail Dresses ... made according to the newest fashion trends. ... dresses for cocktail parties . All of them are ... off. We are making every effort to offer a ...
(Date:12/21/2014)... December 21, 2014 Hundreds of ... liability claims involving a class of Type 2 ... move forward in a federal multidistrict litigation now ... California, Bernstein Liebhard LLP reports. According to an ... a data cut-off date of February 27, 2014 ...
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2
... water ionization and filtration,system designed for home and ... free waters for drinking, cooking, beauty,(skin/hair), cleaning and ... http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA04 ), Called "The Life Science ... the touch of a button, ionizing them through,electrolysis. ...
... Explains the Psychology Behind It, NEW YORK, June ... million for its opening weekend, beating out the new ... comedy has ever,opened with such a lucrative box office. ... Dr. Diana Kirschner, psychologist and,recurring relationship expert on the ...
... developing rheumatoid arthritis by up to 50%, reveals research ... Rheumatic Diseases. , The Scandinavian researchers base their findings ... separate studies, which assessed environmental and genetic risk factors ... (1650) had the disease and had been matched for ...
... on the Federal Government to Ensure Equitable Protections,for ... 4 Trust for America,s,Health (TFAH) issued the ... of Health and Human Services(HHS) Draft Guidances to ... today, emphasizing,that the federal government must do all ...
... blood pressure are the leading causes of kidney,disease, ... United,States. For patients with high blood pressure and ... the progression of kidney disease,which can reduce the ... adults in the US diagnosed with diabetes and ...
... per cent in breast imaging of low risk women, says ... breast ultrasound procedures soared by over 30 per cent among ... breast cancer diagnosis, says a new study from the University ... rise in the number of women aged 25-34 years who ...
Cached Medicine News:Health News:Countertop Appliance Splits Tap Water for Five Uses to Enhance Health, Environment 2Health News:Why is the Sex & the City Movie a Mega-Blockbuster? 2Health News:Regular tipple may curb risk of rheumatoid arthritis 2Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2Health News:MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease 2Health News:MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease 3Health News:Kylie's breast cancer triggered a surge of over 30 percent in breast imaging of low-risk women 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow 4 mm long smooth platform. Serrated handle with polished finish....
Fine 2 mm wide platform. Cross action serrated handle with metal tip guard. Polished finish....
Oval solid 24 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 20 mm. Serrated handle with locking thumb screw and polished finish....
Medicine Products: